Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCD | O00767 | 6/20 | 0.46 |
| ▸ | SCD5 | Q86SK9 | 6/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | UBE2M | P61081 | 1/20 | 0.41 |
| ▸ | DCUN1D1 | Q96GG9 | 1/20 | 0.41 |
| ▸ | SOAT2 | O75908 | 2/20 | 0.40 |
| ▸ | SOAT1 | P35610 | 2/20 | 0.40 |
| ▸ | ACACB | O00763 | 2/20 | 0.40 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.40 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.40 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL855600 | 0.88 | SCD (0.44) | SCDSCD5ALDH1A1UBE2MDCUN1D1 | |
| SCHEMBL855524 | 0.78 | JAK3 (0.38) | ALDH1A1UBE2MDCUN1D1LMNAKMT2A | |
| SCHEMBL854884 | 0.78 | NPSR1 (0.37) | SCDSCD5ALDH1A1LMNAKMT2A | |
| SCHEMBL854157 | 0.75 | SOAT2 (0.47) | ALDH1A1UBE2MDCUN1D1SOAT2SOAT1 | |
| SCHEMBL855625 | 0.74 | SOAT2 (0.52) | ALDH1A1UBE2MDCUN1D1SOAT2SOAT1 | |
| SCHEMBL881090 | 0.73 | NR1H4 (0.34) | SCDSCD5ALDH1A1UBE2MDCUN1D1 | |
| SCHEMBL881103 | 0.72 | ACACB (0.39) | SCDSCD5ALDH1A1ACACBKMT2A | |
| SCHEMBL855597 | 0.72 | SOAT1 (0.41) | SOAT1 | |
| Hydrochloric Acid SCHEMBL855630 | 0.72 | NR1H4 (0.34) | SCDSCD5ALDH1A1UBE2MDCUN1D1 | |
| SCHEMBL881081 | 0.72 | SOAT2 (0.55) | UBE2MDCUN1D1SOAT2SOAT1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1308438-B9 | 3-SUBSTITUTED UREA DERIVATIVES AND MEDICINAL USE THEREOF | MITSUBISHI TANABE PHARMA CORP (JP) | 2012-03-28 | — | — | EP | disclosed |
| EP-1308438-B1 | 3-SUBSTITUTED UREA DERIVATIVES AND MEDICINAL USE THEREOF | MITSUBISHI TANABE PHARMA CORP (JP) | 2010-10-20 | — | — | EP | disclosed |
| US-7105567-B2 | 3-substituted urea derivatives and medicinal use thereof | MITSUBISHI PHARMA CORPORATION (JP) | 2006-09-12 | — | — | US | disclosed |
| US-20030207939-A1 | Novel 3-substituted urea derivatives and medicinal use thereof | MITSUBISHI PHARMA CORPORATION (JP) | 2003-11-06 | — | — | US | disclosed |
| EP-1308438-A1 | 3-SUBSTITUTED UREA DERIVATIVES AND MEDICINAL USE THEREOF | Mitsubishi Pharma Corporation (JP) | 2003-05-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030207939-A1 | Novel 3-substituted urea derivatives and medicinal use thereof | C5AR1, C5AR2, C3AR1 | SCD 2456/4885SCD5 1813/4885ALDH1A1 2416/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.